The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPATH.L Regulatory News (PATH)

  • There is currently no data for PATH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Equity Fundraise Update

26 Feb 2021 07:00

RNS Number : 4266Q
Path Investments plc
26 February 2021
 

26 February 2021

Path Investments plc

("Path" or the "Company")

Equity Fundraise Update

 

 

Path Investments plc (TIDM: PATH), the energy and natural resources investment company, is pleased to announce that further to the announcement of the Company's conditional £3.5 million fundraise on 19 February 2021, it has conditionally raised (before expenses) an additional £350,000 in order to satisfy certain demand from existing shareholders (the "Subscription").

 

The Subscription is on the same terms as the previously announced Fundraise and is for 140,000,000 new ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") (the "Subscription Shares") at a price of 0.25 pence per Ordinary Share. In addition, participants in the Subscription will be issued with one warrant for every two Subscription Shares subscribed for with an exercise price of 0.25 pence per Ordinary Share and one warrant for every two Subscription Shares subscribed for with an exercise price of 0.5 pence per Ordinary Share (the "Warrants"). The Warrants will have a five-year exercise period from the date of grant.

 

The Subscription and the previously announced £3.5 million Fundraise are conditional on the publication of a prospectus and admission of the Subscription and Placing Shares to trading on the Standard Segment of the Official List and the Main Market of the London Stock Exchange ("Admission"). The prospectus is currently being prepared and will be published following the grant of the required Financial Conduct Authority ("FCA") approval. In the interim, the Company's existing issued shares shall continue to trade and the expected date of Admission will be announced in due course.

 

Capitalised terms not otherwise defined in this announcement have the same meaning as in the Company's announcement on 19 February 2021.

 

Commenting, Christopher Theis CEO of Path, said: "Following the announcement of our £3.5 million fundraise we were made aware of demand from certain significant existing shareholders that had not been accommodated already. We are therefore pleased to increase the overall size of the fundraise in order to accommodate them and raise further funds to help facilitate our search for acquisition opportunities in line with our investment strategy. We look forward to concluding the prospectus approval process in the coming weeks and I look forward to providing further updates in due course."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

For further information please contact:

Path Investments plc

C/O IFC

Christopher Theis

Jack Allardyce

IFC Advisory (Financial PR & IR)

020 3934 6630

Tim Metcalfe

Zach Cohen

Grant Thornton UK LLP (Financial Adviser)

Jamie Barklem

Samantha Harrison

Harrison Clarke

020 7383 5100

 

ETX Capital (Broker)

020 7392 1400

Elliot Hance

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOESEDFUIEFSEDE
Date   Source Headline
7th Apr 20227:00 amRNSUpdate on Acquisition
5th Apr 20227:00 amRNSInvestor Presentation
1st Apr 20222:45 pmRNSResult of General Meeting
14th Mar 20221:09 pmRNSPublication of Prospectus, Notice of GM, Fundraise
1st Feb 20227:00 amRNSProposed Transaction Update
31st Dec 20217:00 amRNSProposed Transaction Update
18th Nov 20217:00 amRNSAppointment of Joint Broker
26th Oct 20217:00 amRNSProposed Transaction Update
13th Oct 20216:02 pmRNSCorrection: Holding(s) in Company
13th Oct 20214:52 pmRNSHolding(s) in Company
11th Oct 20217:00 amRNSBlock listing Interim Review
29th Sep 20217:00 amRNSInterim Results for the six months to 30 June 2021
28th Sep 20212:45 pmRNSResult of AGM
22nd Sep 20212:41 pmRNSFurther secured loan provided to DG Innovate
9th Sep 20216:01 pmRNSHolding(s) in Company
2nd Sep 20217:00 amRNSNotice of AGM
18th Aug 202111:54 amRNSCorrection: Holding(s) in Company
18th Aug 20217:00 amRNSHolding(s) in Company
13th Aug 20217:45 amRNSProposed Acquisition of DG Innovate & Suspension
14th Jul 20215:23 pmRNSHolding(s) in Company
14th Jul 20212:39 pmRNSHolding(s) in Company
24th Jun 20217:00 amRNSFinal Results for the Year Ended 31 December 2020
16th Jun 20217:00 amRNSHolding(s) in Company
8th Jun 202111:49 amRNSHolding(s) in Company
7th Jun 202112:04 pmRNSHolding(s) in Company
9th Apr 202110:03 amRNSHolding(s) in Company
9th Apr 20217:00 amRNSBlock Listing
1st Apr 20215:02 pmRNSHolding(s) in Company
31st Mar 20219:55 amRNSTotal Voting Rights
24th Mar 20212:06 pmRNSDirector/PDMR Share Transaction
19th Mar 20218:53 amRNSHolding(s) in Company
12th Mar 20215:36 pmRNSAdmission of previously issued shares
12th Mar 202112:50 pmRNSPublication of Prospectus
8th Mar 202111:05 amRNSSecond Price Monitoring Extn
8th Mar 202111:00 amRNSPrice Monitoring Extension
1st Mar 20214:41 pmRNSSecond Price Monitoring Extn
1st Mar 20214:36 pmRNSPrice Monitoring Extension
26th Feb 20212:06 pmRNSSecond Price Monitoring Extn
26th Feb 20212:00 pmRNSPrice Monitoring Extension
26th Feb 20217:00 amRNSEquity Fundraise Update
19th Feb 20217:00 amRNS£3.5 million Equity Fundraise
15th Feb 20212:00 pmRNSTermination of DTU Acquisition
3rd Dec 20209:44 amRNSSubscription for £55,000 of Convertible Loan Stock
5th Nov 20207:00 amRNSFurther re the Acquisition of 75% of DT Ultravert
8th Oct 20209:55 amRNSOption Surrender and Issue of Replacement Options
5th Oct 20207:00 amRNSProposed sale of Kansas Land Leases and equipment
1st Oct 202011:41 amRNSFurther re the Acquisition of DT Ultravert
30th Sep 20207:00 amRNSBoard Changes & Acquisition of Deferred Shares
10th Sep 20201:30 pmRNSInterim Results for the six months to 30 June 2020
10th Sep 20201:15 pmRNSFinal Results for the Year Ended 31 December 2019

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.